Mark Nedelman
Vorstandsvorsitzender bei Biomedical Research Models, Inc.
Profil
Mark Nedelman is the Chief Executive Officer at Biomedical Research Models, Inc. He previously worked as the Associate Director-Preclinical Pharmacology at Centocor, Inc., Senior Director-Business Development at SelectX Pharmaceuticals, Inc., and General Manager-Preclinical Services at Charles River Laboratories, Inc.
Aktive Positionen von Mark Nedelman
| Unternehmen | Position | Beginn |
|---|---|---|
Biomedical Research Models, Inc.
 Biomedical Research Models, Inc. BiotechnologyHealth Technology Biomedical Research Models, Inc. develops and utilizes specialty animal models to determine the efficacy of new drugs in preventing or ameliorating human diseases. It offers contract research, proprietary models,colony management, and partnership services. The company was founded by Dennis L. Guberski in 1996 and is headquartered in Worcester, MA. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Mark Nedelman
| Unternehmen | Position | Ende |
|---|---|---|
Charles River Laboratories, Inc.
 Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Technik-/Wissenschafts-/F&E-Leiter | - |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
Charles River Laboratories, Inc.
Charles River Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA. | Commercial Services |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Biomedical Research Models, Inc.
Biomedical Research Models, Inc. BiotechnologyHealth Technology Biomedical Research Models, Inc. develops and utilizes specialty animal models to determine the efficacy of new drugs in preventing or ameliorating human diseases. It offers contract research, proprietary models,colony management, and partnership services. The company was founded by Dennis L. Guberski in 1996 and is headquartered in Worcester, MA. | Health Technology |
